P352: TDM of infliximab in IBD-patients: which pharmacokinetic marker to use?
ECCO '19 Copenhagen
2019
P354: Perceived Quality of Care is associated to quality of life, work productivity and gender but not disease phenotype: a prospective study in a high-volume IBD centre
ECCO '19 Copenhagen
2019
P356: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in paediatric patients with inflammatory bowel disease: a multi-centre cohort study
ECCO '19 Copenhagen
2019
P357: Serological biomarkers of interstitial matrix and basement membrane remodelling correlate to disease activity in Crohn’s disease
ECCO '19 Copenhagen
2019
P358: Ustekinumab is effective for the treatment of chronic antibiotic-refractory pouchitis
ECCO '19 Copenhagen
2019
P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity
ECCO '19 Copenhagen
2019
P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD
ECCO '19 Copenhagen
2019
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
ECCO '19 Copenhagen
2019
P363: The minimal invasive surgery in combination with negative pressure wound therapy for perianal fistulas in Crohn’s colitis lead to the fast introduction of the biological treatment and improve the results
ECCO '19 Copenhagen
2019
P364: The value of faecal calprotectin for assessing endoscopic activity and predicting future clinical course in patients with active ulcerative colitis treated with granulomonocytapheresis: a prospective study
ECCO '19 Copenhagen
2019
P365: Autologous haematopoietic stem cell transplantation in refractory Crohn’s disease: experience of a Brazilian tertiary centre
ECCO '19 Copenhagen
2019
P366: A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition
ECCO '19 Copenhagen
2019
P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention
ECCO '19 Copenhagen
2019
P368: Vedolizumab in inflammatory bowel disease: a retrospective single-centre study
ECCO '19 Copenhagen
2019
P369: The comparative frequency of clostridial infection in patients with ulcerative colitis receiving mesenchymal stromal cells and anti-cytokine therapy
ECCO '19 Copenhagen
2019